| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $374,998 | 2 | 100 |
Sells | $0 | 0 | 0 |
| Samuel Olivier | director | 1 | $225,000 | 0 | $0 | $225,000 |
| Revel Michel | CSO and Director | 1 | $149,999 | 0 | $0 | $149,999 |
NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich, Switzerland, is dedicated to advancing groundbreaking therapeutic solutions. The company's focus lies in developing innovative treatments, utilizing both cell-based and small-molecule approaches, to address challenging neurodegenerative and metabolic diseases.
Over the last 12 months, insiders at NewcelX Ltd. have bought $374,998 and sold $0 worth of NewcelX Ltd. stock.
On average, over the past 5 years, insiders at NewcelX Ltd. have bought $374,998 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Samuel Olivier (director) — $225,000. Revel Michel (CSO and Director) — $149,999.
The last purchase of 54,545 shares for transaction amount of $149,999 was made by Revel Michel (CSO and Director) on 2026‑04‑27.
| 2026-04-27 | Revel Michel | CSO and Director | 54,545 8.6132% | $2.75 | $149,999 | -14.47% | ||
| 2026-04-27 | Samuel Olivier | director | 81,818 12.9199% | $2.75 | $225,000 | -14.47% |
| Increased Positions | 0 | 0% | 0 | 0% |
| Decreased Positions | 3 | -50% | 14,373 | -99.98% |
| New Positions | 0 | New | 0 | New |
| Sold Out Positions | 2 | Sold Out | 14,372 | Sold Out |
| Total Postitions | 3 | -50% | 3 | -99.98% |